Single peptide Vial strength 30 mg
PNC-2730 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
PNC-27, explained simply
A synthetic peptide studied in laboratory models for its interaction with tumour cells; human clinical studies are lacking.
Research area
Preclinical oncology
How it works
PNC-27 is a synthetic peptide designed to interact with components of the p53/HDM2 pathway and the cell membrane.
Why it matters
Its profile helps distinguish laboratory anticancer hypotheses from treatments studied in humans.
What has been observed
Findings are reported from cell and preclinical models, without human clinical trials.
Effects and points to consider
Clinical efficacy and safety have not been established for this compound.
01 / Vial strength 30 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 30 mg PNC-27 |
|---|---|
| Final volume | 3 mL |
| Concentration | 10 mg/mL |
| One U-100 unit | 100 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = 10 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 1 unit (0.01 mL) |
| Weeks 3–4 | 200 mcg (0.20 mg) | 2 units (0.02 mL) |
| Weeks 5–8 | 300 mcg (0.30 mg) | 3 units (0.03 mL) |
| Weeks 9–12 | 400 mcg (0.40 mg) | 4 units (0.04 mL) |
| Weeks 13–16 | 500 mcg (0.50 mg) | 5 units (0.05 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.